Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization
Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization
复制标题
DOI：
10.7150/ijbs.39534
复制
发表时间：
2019-01-01
影响因子：
9.2
通讯作者：
Wang, Xin Wei
中科院分区：
文献类型：
--
作者：
Fako, Valerie;Martin, Sean P.;Wang, Xin Wei
经动脉化疗栓塞（TACE）是肝细胞癌（HCC）的常用治疗方式。识别对TACE有反应的患者的能力代表了重要的临床需求，并且肿瘤基因表达模式可能与TACE反应相关。我们研究了肿瘤转录组是否与肝癌患者的TACE反应相关。我们分析了来自191名中国HCC患者队列的未经治疗的肿瘤组织的转录组数据，其中包括105名在切除后接受TACE治疗的患者。然后，我们开发了一种基因标签，TACE Navigator，它与接受辅助或复发后TACE的患者的生存率提高相关。为了验证我们的发现，我们以盲态方式将我们的签名应用于三个独立的队列，包括另外130名在三家不同医院登记的具有不同种族背景的患者，这些患者接受了辅助TACE或姑息性TACE。TACE Navigator将患者分层为应答者和非应答者，这与我们测试队列中TACE后的生存率改善相关（应答者：67个月vs非应答者：39.5个月，p
Transarterial chemoembolization (TACE) is a commonly used treatment modality in hepatocellular carcinoma (HCC). The ability to identify patients who will respond to TACE represents an important clinical need, and tumor gene expression patterns may be associated with TACE response. We investigated whether tumor transcriptome is associated with TACE response in patients with HCC. We analyzed transcriptome data of treatment-naive tumor tissues from a Chinese cohort of 191 HCC patients, including 105 patients who underwent TACE following resection with curative intent. We then developed a gene signature, TACE Navigator, which was associated with improved survival in patients that received either adjuvant or post-relapse TACE. To validate our findings, we applied our signature in a blinded manner to three independent cohorts comprising an additional 130 patients with diverse ethnic backgrounds enrolled in three different hospitals who received either adjuvant TACE or palliative TACE.TACE Navigator stratified patients into Responders and Non-Responders which was associated with improved survival following TACE in our test cohort (Responders: 67 months vs Non-Responders: 39.5 months, p